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Open access under CC The lysine acetyltransferase CREB binding protein (CBP) is required for chromatin modiﬁcation and tran-
scription at many gene promoters. In ﬁxed cells, a large proportion of CBP colocalises to PML or nuclear
bodies. Using live cell imaging, we show here that YFP-tagged CBP expressed in HEK293 cells undergoes
gradual accumulation in nuclear bodies, some of which are mobile and migrate towards the nuclear enve-
lope. Deletion of a short lysine-rich domain that contains the major SUMO acceptor sites of CBP abrogated
its ability to be SUMO modiﬁed, and prevented its association with endogenous SUMO-1/PML speckles
in vivo. This SUMO-defective CBP showed enhanced ability to co-activate AML1-mediated transcription.
Deletion mapping revealed that the SUMO-modiﬁed region was not sufﬁcient for targeting CBP to PML
bodies, as C-terminally truncated mutants containing this domain showed a strong reduction in accumu-
lation at PML bodies. Fluorescence recovery after photo-bleaching (FRAP) experiments revealed that
YFP–CBPD998–1087 had a retarded recovery time in the nucleus, as compared to YFP–CBP. These results
indicate that SUMOylation regulates CBP function by inﬂuencing its shuttling between nuclear bodies
and chromatin microenvironments.
 2009 Elsevier Inc. Open access under CC BY license.Introduction [8,9] and SUMOylation [10] which regulate its functional interac-CBP is a large multi-domain nuclear protein that interacts with
and acetylates histones and other nuclear proteins [1]. This facili-
tates its function as a coactivator of gene transcription, as recruit-
ment of CBP to active promoters correlates with histone
hyperacetylation and gene activation. Recruitment of CBP to active
gene promoters/enhancers is transient and often dependent on an
activating signal, e.g. at genes that are induced by signal transduc-
tion events or hormone ligands. This suggests that CBP mobility in
the nucleus is highly dynamic, and thus tightly regulated. Antibody
staining of CBP in ﬁxed cells reveals that a large proportion of nu-
clear CBP is localised in nuclear bodies (also called PML bodies) [2]
from where it shuttles to sites of transcription. Currently, little is
known regarding how this is achieved, although it is likely to be
dependent on protein–protein interactions, and post-translational
modiﬁcation of CBP.
CBP is subjected to a range of post-translational modiﬁcations
including acetylation [3], phosphorylation [4–7], ubiquitylationr; CBP, CREB binding protein;
myelocytic leukaemia; AML,
ylase; HDAC, histone deace-
hing; CRD, cell cycle repres-
.M. Heery).
BY license.tions, activity and stability. SUMOylation of CBP occurs within a re-
gion containing eight potential SUMO acceptor sites (amino acids
998–1090), andmediates interaction of CBPwith the transcriptional
corepressorsDaxx andHDAC6 [10–12]. Our studies have shown that
interactions between CBP and the leukaemogenic fusion protein
MOZ-TIF2 [13] or cytoplasmic isoforms of PML [14] can sequester
it away from nuclear bodies, and that in the case of MOZ-TIF2, CBP
binding is necessary for leukaemogenesis [13]. Thus, dynamic asso-
ciationwith nuclear bodies appears to be an important aspect of the
normal function of CBP. In this study we investigate the localisation
of YFP–CBP to nuclear bodies in live cells, and investigate the role of
the SUMOylated domain of CBP in this process.
Materials and methods
Expression and reporter plasmids. The following expression and
reporter plasmids were gifts; pCMV5 AML1b (D.E. Zhang), pT109-
luc (A. Zelent), pSG5 HA-SUMO-1 (V. Di Laurenzo), HA-TDG
(S. Ali), pEGFP SUMO-1, pEGFP-SUMO-1(G/A) (J. Palvimo) and
pcDNA3.1-FLAG-CBP (E. Kalkhoven). The b-galactosidase reporter
pCH110 (Promega) was used as an internal control in reporter as-
says. YFP–CBP was generated by subcloning a BamHI fragment
containing full-length mouse CBP cDNA from pRSV-CBP-HA
(R. Goodman) into pEYFP-C1 (Clontech). Recombinant PCR was
used to introduce a deletion of the sequence encoding amino acids
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the deletion series pcDNA3.1-FLAG-CBP 1–507, 1–1100, 1–1458
and 1–1901 by digestion with BlnI, XbaI, XhoI and XmaI restriction
endonucleases, respectively, followed by gel puriﬁcation and re-
ligation of the appropriate fragments. All deletion boundaries or
PCR generated constructs were veriﬁed by sequencing.
Reporter assays. COS-1 cells were maintained in Dulbecco’s
modiﬁed eagle medium (DMEM) supplemented with 10% foetal
calf serum (FCS) and 2 mM glutamine at 5% CO2. AML1 reporter as-
says, were performed essentially as described previously [23] using
100 ng b-galactosidase reporter pCH110, 500 ng of the AML1-
responsive reporter pT109-luc, 100 ng AML1 and 500 ng of the
other expression vectors along with empty vector to standardise
the quantity of transfected DNA in each well. The luciferase activity
data was normalised for b-galactosidase activity.
In vitro SUMOylation assay. The expression constructs used in
the SUMOylation assay were in vitro transcribed and translated
using TNT coupled reticulolysate system (Promega) to produce
35S-methionine labelled proteins. Reaction mixtures contained
equal amounts of the 35S-labelled IVT protein, recombinant SAE1/
SAE2 (0.1 lg), Ubc9 (0.45 lg), SUMO-1 or SUMO-2 (1 lg) (Alexis
Biochemicals) in SUMO conjugation buffer (50 mM Tris pH 7.5,
10 mM MgCl2, 5 mM ATP, 0.2 mM DTT), and were incubated at
30 C for 2 h. The reactions were stopped by the addition of
4XSDS-loading buffer and incubated at 95 C for 5 min. The pro-
teins were resolved on 6% or 10% SDS–PAGE gels and proteins vis-
ualised using a phosphorimager.
Immunoﬂuorescence. Transfections were performed using Trans-
Fast (Promega). Immunostaining of ﬁxed cells was performed as
previously described [13]. Fixed cells were stained with primary
antibodies for 1 h (1:50 dilution for overexpressed proteins, 1:10
for CBP, 1:30 for PML, 1:100 for SUMO-1 and 1:30 for FLAG). After
washing to remove unbound primary antibody, cells were incu-
bated with the secondary antibody (1:400 dilution). The samples
were viewed with a ﬂuorescence microscope (Zeiss Axiovert
200 M) or a confocal laser scanning microscope (Zeiss LSM510).
Live cell imaging. Cells were seeded at a density of 5  105 cells
on 22-mm-diameter circular coverslips for 24 h, followed by trans-
fection with 1 lg of pEYFP–CBP. At 14 h post-transfection, the cov-
erslip was mounted in a steel coverslip holder in CO2-independent
medium (Invitrogen) supplemented with L-glutamine and overlaid
with mineral oil (Sigma). The coverslip holder was inserted in a
Patch Slice MicroIncubator, which was kept at a constant temper-
ature of 37 C by a TC-202A temperature controller (Digitimer).
After the microincubator was mounted on the microscope stage,
images were taken at 5-min intervals with an ORCA ER charge-cou-
pled-device camera (Hamamatsu) attached to a Nikon TE300 in-
verted microscope. Five optical sections (z-sections) with 0.1 lm
intervals, obtained with a high-speed Piezo focus drive (Orbit II)
ﬁxed to a 60, 1.4-numerical-aperture objective, were captured
at the individual time points by using Openlab 3.09 software
(Improvision). The individual sections were merged by using the
Openlab software, processed with Adobe Photoshop, and saved as
a quick-time movie. Stills were made with Volocity software
(Improvision).
Fluorescence recovery after photo-bleaching (FRAP). Cells were
seeded and observed in 8 well LabTek chamber slides (Nunc) in
DMEM, supplemented with 10% foetal calf serum and 1% L-Gluta-
mine. FRAP experiments were performed 24 h post-transfection
(250 ng of YFP–CBP or YFP–CBPD998–1087 expression plasmids).
Bleaching was performed using a 488 nm laser at 100% output
for 1.3 s and 100 iterations were performed to optimise bleaching
of the selected region of interest (ROI). Nucleolar regions were ex-
cluded in the choice of ROIs. The laser output was attenuated to 1%
output for imaging to minimise bleaching and phototoxicity. Single
z-sections were collected in 12-bit format before bleaching, di-rectly after and every 10 s thereafter for 2 min. Mean ﬂuorescent
intensities of chosen ROIs were determined using the LSM software
and data was exported to Excel (Microsoft Inc.) for analysis. Curves
were ﬁtted using Sigma Plot 11.0 and Standard Error of the Mean is
shown for the indicated time points.
Results
CBP nuclear bodies are mobile and can migrate toward the nuclear
periphery
To study the subcellular localisation of CBP in live cells, HEK293
cells were transiently transfected with YFP–CBP expression plas-
mids [13] and monitored 12–18 h post-transfection. Cells showing
moderate levels of YFP–CBP expression were chosen for time-lapse
imaging. As shown in Fig. 1, at approximately 14 h post-transfec-
tion (designated t = 0) YFP–CBP proteins displayed a diffuse nucle-
ar distribution, excluded from nucleoli. However, time-lapse
imaging for a further 4 h revealed gradual accumulation of YFP–
CBP in nuclear bodies. This gradual accumulation of nascent YFP–
CBP proteins in nuclear bodies suggests it may be dependent on
protein–protein interactions, post-translational modiﬁcations or
turnover of CBP proteins not targeted to nuclear bodies. Viewed
as a time-lapse movie, it was observed that some YFP–CBP speckles
showed considerable mobility within the nucleus, whereas other
speckles appear to remain largely static. This is highlighted in
the insets (Fig. 1G–T, top left corners) where some speckles (e.g.
Fig. 1G) remain relatively unchanged during image capture,
whereas others appear to move distances of at least 1 lm (e.g.
compare with Fig. 1L–T). Similar observations have been reported
previously for another PML body component, i.e. SP100, where a
proportion of GFP-SP100-containing nuclear speckles were found
to move in an ATP-dependent manner [15].
SUMOylation-defective CBP does not accumulate in PML bodies
CBP is SUMOylated within a region containing a cluster of lysine
residues that is partially conserved within p300 [10,11]. We gener-
ated a construct in which this region was removed (YFP–
CBPD998–1087). In vitro assays conﬁrmed that while full-length
CBP or thymine DNA glycosylase (TDG) proteins can be efﬁciently
conjugated to SUMO-1 or SUMO-2 in a Ubc9-dependent manner,
the YFP–CBPD998–1087 mutant did not show any mobility shift
due to SUMOylation in these assays (Fig. 2A). This conﬁrms that
the YFP–CBPD998–1087 mutant is defective for SUMOylation.
However, deletion of the SUMOylated region did not affect the
ability of CBP to localise to the nucleus (Figs. 2C and 4A) or its func-
tion as a coactivator. Indeed, reporter assays revealed that YFP–
CBPD998–1087 displayed an enhanced ability to stimulate
AML1-mediated reporter activation. As shown in Fig. 2B, expres-
sion of AML1 alone led to an approximately fourfold increase in re-
porter activation, which increased to eightfold upon co-expression
with YFP–CBP. However, the reporter was activated 12-fold by co-
expression of AML1 and YFP–CBPD998–1087 (Fig. 2B), despite
being expressed to similar levels as determined by western blots
(data not shown). This result is consistent with other reports that
SUMOylation of p300 and CBP may suppress coactivator activities,
possibly through recruitment of HDAC complexes [12], and that a
SUMO-defective CBP showed increased coactivator activity in
IRF1 reporter assays [10].
To determine whether YFP–CBPD998–1087 can localise to PML
bodies, we expressed it in COS-1 cells. As shown in Fig. 2C, YFP–
CBPD998–1087 was detected in large numbers of smaller foci
(microspeckles) in approximately 90% of transfected (ﬁxed) cells.
Co-staining of these cells with a-SUMO-1 to reveal nuclear bodies
showed that the YFP–CBPD998–1087 microspeckles are distinct
Fig. 1. Time-lapse imaging of YFP–CBP. HEK293 cells were transfected with 1 lg pEYFP–CBP expression plasmid. Image capture was initiated approximately 14 h post-
transfection at 5 min intervals for 4 h. The images shown were deconvolved and merged to produce the composite images. The insets in the top left hand corner show a higher
magniﬁcation of the selected region, highlighting the formation of CBP-containing nuclear bodies and their relative migration during the experiment.
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lates in PML bodies, we expressed GFP-SUMO or a GFP-SUMO
(G/A) mutant that cannot undergo conjugation to acceptor proteins
[16]. The GFP-SUMOwas found to accumulate in PML bodies, as re-
vealed by staining for endogenous nuclear CBP (Fig. 2D). Note that
endogenous PML and CBP proteins show perfect colocalisation in
these experiments ([18] and data not shown). However, unlike
GFP-SUMO, GFP-SUMO (G/A) revealed a diffuse nuclear pattern
that was not enriched in PML bodies (Fig. 2D). Quantitation of sub-
cellular distribution phenotypes in transfected cell nuclei (n = 100)
revealed that GFP-SUMO was detected in nuclear speckles in 90%
or 68% of COS-1 or HEK293 cells, respectively, compared with
10% or 0%, respectively for GFP-SUMO(G/A) (data not shown).
The C-terminus of CBP is necessary for efﬁcient SUMOylation and
targeting to nuclear bodies
To determine if other sequences in CBP contribute to SUMOyla-
tion, in vitro SUMO assayswere performed using a series of C-termi-
nally truncated FLAG-CBP proteins that sequentially deletes
functional domains such as the SID (1–1901), CH3 (1–1458), CH2/
HAT/Bromo (1–1100) and CH1/KIX (1–507) domains (Fig. 3A). Sur-
prisingly, only full-length CBP (Fig. 2A) and to a lesser extent CBP
1–1901 (Fig. 3B) were SUMOylated in vitro, despite the presence of
the SUMO targeted region in CBP 1–1458 and 1–1100. This suggests
that sequences in the C-terminus of CBP may be important to facili-
tate SUMOylation. Transient expression of these constructs in COS-1
(Fig. 3C) or HEK293 cells (not shown) revealed that while all of the
truncated CBP proteins were nuclear, only full-length CBP showed
a strong association with nuclear bodies. Thus, sequences at theC-terminus of CBP are required both for efﬁcient Ubc9-dependent
SUMOylation of CBP, and for targeting of CBP to nuclear bodies.
SUMO-defective CBP shows reduced mobility in the nucleoplasm
To determine whether SUMO modiﬁcation of CBP alters its
dynamic mobility in the nucleoplasm, FRAP experiments were per-
formed using COS-1 cells expressing YFP–CBP or YFP–CBPD998–
1087. Cells showing similar levels of expression and typical
subcellular distributions of the recombinant YFP proteins were se-
lected forphoto-bleaching.WhileYFP–CBPwas found to accumulate
in nuclear bodies as before (Fig. 3A, upper panels) YFP–CBPD998–
1087 in live cells showed an accumulation in microspeckles
(Fig. 3A, lower panels), similar to that observed in ﬁxed cells
(Fig. 2C). Photo-bleaching was performed on a deﬁned region of
interest as described in ‘Materials and Methods’, under conditions
where bleaching did not affect neighbouring YFP positive cells (data
not shown). FRAP was performed on three individual cells each for
YFP–CBP and YFP–CBPD998–1087, selecting cells showing typical
nuclear distributions. As shown for representative cells in Fig. 4A,
both YFP–CBP and YFP–CBPD998–1087 were able to repopulate
the bleached areas. The mean ﬂuorescence recovery half-time for
YFP–CBP in COS-1 cells was determined as 19 s. However, YFP–
CBPD998–1087 displayed a retarded mobility half-time (Fig. 4B)
displaying a mean ﬂuorescence recovery half-time of 45 s. Both the
rate and extent of recovery were reduced, as shown by the plateau
of recovery at a lower percentage of the total initial ﬂuorescence
(Fig. 4B). These results indicate a reduced mobility of the SUMOyla-
tion-defective mutant CBP in the nucleoplasm, and suggest that
SUMOmodiﬁcation regulates themobility of CBP in the nucleoplasm,
Fig. 2. (A) SUMO-defective CBP. Mouse CBP, CBPD998–1087 and TDG were in vitro translated in the presence of [35S]-methionine to give full-length radio-labelled proteins.
The IVT proteins were then used for in vitro SUMO assays using recombinant Ubc9, SAE1/SAE2 and SUMO-1 or SUMO-2, as indicated. The proteins were resolved via SDS–
PAGE prior to autoradiography. SUMOylated CBP and TDG proteins are indicated by asterices. (B) Deletion of the residues 998–1087, corresponding to the cell cycle regulatory
domain (CRD) of p300 (11), enhances CBP coactivation of AML1. Transient transfection experiments using the AML1-responsive luciferase reporter pT109-luciferase. The
effect of the indicated CBP or CBPD998–1087 constructs on AML1-mediated reporter activation is shown. The data is represented as fold induction luciferase reporter activity
(normalised to b-galactosidase) over the control (no AML1). A representative experiment is shown, with standard errors of the mean from triplicate samples. (C)
Mislocalisation of a SUMO-defective CBP. Distribution of YFP–CBPD998–1087 in ﬁxed COS-1 cells (left panel,) immunostained for endogenous SUMO-1 proteins (middle
panel). (D) Detection of GFP-SUMO-1 or non-conjugable GFP-SUMO-1 G/A mutant proteins in COS-1 cells. After ﬁxing, cells were immunostained for endogenous CBP to label
nuclear bodies (middle panels). Merged images are also shown (right panels).
Fig. 3. Sequences outside the CRD are required for efﬁcient SUMOylation of CBP and targeting to nuclear bodies. (A) Schematic representation showing the domain structure of full-
length CBP, CBPD998–1087 and CBP C-terminal deletion mutants used. (B) In vitro SUMO assays using CBP proteins, as described in the legend to Fig. 2B. (C) Immunostaining
of FLAG-CBP polypeptides in ﬁxed COS-1 cells, using anti-FLAG antibodies. The images shown are typical nuclear distribution patterns for each construct. The scale bar is
equivalent to 2 lm.
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Fig. 4. SUMOylation inﬂuences the mobility of CBP in the nucleoplasm. Fluorescence recovery after photo-bleaching (FRAP) analyses was performed on COS-1 cells expressing
YFP–CBP or YFP–CBPD998–1087. (A) Representative images for YFP fusion proteins shown before bleaching (pre-Bleach), immediately after the bleaching (bleach) and at the
indicated times thereafter (post-bleach). The bleached region of interest is boxed. Scale bar represents 5 lm. (B) Fluorescence recovery curves for YFP–CBP (black squares)
and YFP–CBP (grey circles) showing the kinetics of redistribution post-bleaching. Best ﬁt curves were generated using Sigmaplot software and standard error of the mean is
shown for each time point.
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matin or macromolecular structures such as nuclear bodies.
Discussion
Using confocal microscopy and live cell imaging techniques, we
have shown here that following an initial diffuse nuclear localisa-
tion, YFP–CBP proteins gradually accumulate in nuclear bodies.
This targeting to nuclear bodies is dependent on the region of
CBP that is subject to SUMO modiﬁcation, in addition to sequences
in the C-terminus. A proportion of the nuclear bodies containing
YFP–CBP were observed to move relatively large distances within
the nucleoplasm (up to 1 lm), consistent with a previous report
that a proportion of GFP-SP100 nuclear speckles display mobility
within the nucleus [15]. We noted that some of the YFP–CBP speck-
les form at the nuclear periphery and appear to move along the
axis of the nuclear membrane. This phenomenon was observed
in all three of the YFP–CBP expressing cells imaged in Fig. 1, and
in other time-lapse experiments (data not shown). Failure to ob-
serve this in ﬁxed cells is likely to be due to the collapse of the cel-
lular integrity under conditions of ﬁxation.
The juxtapositioning of CBP-containing nuclear bodies near the
nuclear membrane is of interest given recent ﬁndings of functional
interactions between CBP, nucleoporins and nuclear transport pro-
teins [17,18]. Indeed nuclear transport proteins have been shown
to bind chromatin and function in gene regulation [19,20]. CBPhas been reported to interact directly with nucleoporins NUP98
and NUP153 via the FG repeats, which also mediate its interaction
with NUP98-HOXA9 fusion protein associated with acute myeloid
leukaemia [21]. We also reported the isolation of NUP93 heptad re-
peat domain in a yeast two-hybrid screen for proteins that bind the
C-terminus of CBP [18]. Moreover, CBP forms a complex with
importin-a and its exportin (CAS) via a LLXXLXXLL type motif in
CAS, resulting in acetylation of importin-a [18], as necessary for
its recycling to the cytoplasm [17]. Interestingly, another lysine
acetyltransferase (MOF) has also been reported to associate with
nuclear pore components, in complexes targeted to the nuclear
periphery, which are involved in transcriptional regulation of dos-
age compensation in drosophila and mammalian cells [22].
Freely mobile proteins quickly recover almost 100% ﬂuores-
cence in FRAP experiments, whereas less mobile proteins such as
PML show very long recovery times, and plateau at a level of ﬂuo-
rescence less than 100% [2]. In our FRAP experiments, the time ta-
ken for YFP–CBP to recover 50% ﬂuorescence in COS-1 cells was
19 s (Fig. 4B). However, the SUMO-defective CBP protein exhibited
a longer recovery time, suggesting that the SUMOylated CBP pro-
teins have increased mobility in the nucleoplasm. SUMOylation
may decrease the residency time of CBP on chromatin at active
gene promoters/enhancers. Alternatively, SUMO modiﬁcation
may alter the ability of CBP to interact with other nuclear proteins.
In summary, we have demonstrated here that the gradual accu-
mulation of recombinant YFP–CBP proteins in nuclear bodies in
C.M. Ryan et al. / Biochemical and Biophysical Research Communications 391 (2010) 1136–1141 1141live cells is dependent on a domain that contains the major SUMO
modiﬁcation sites in CBP. This region, in conjunction with C-termi-
nal CBP sequences, acts to facilitate association of CBP with nuclear
bodies. Moreover, a CBP mutant lacking this domain showed al-
tered coactivator activity in AML1-dependent reporter assays,
and reduced mobility in the nucleoplasm in FRAP experiments.
Thus, post-translational modiﬁcation of CBP by SUMO proteins is
likely to inﬂuence the mobility of CBP in the nucleoplasm, its abil-
ity to associate with nuclear proteins and accumulate in nuclear
bodies, and its function as a transcriptional coactivator.
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